About Multiple Sclerosis Foundation

Home > Learn About Multiple Sclerosis > News > Supreme Court to Rule on Copaxone® Patent Dispute

Supreme Court to Rule on Copaxone® Patent Dispute


The U.S. Supreme Court agreed to hear an appeal by Teva Pharmaceutical Industries Ltd. to revive a patent that would protect Copaxone® from generic rivals until September 2015. Without that patent, Teva would lose legal protection on Copaxone this May.

With this latest development, a company that begins selling a generic Copaxone in May might eventually have to pay Teva for lost sales if the Supreme Court rules in Teva's favor. Such a decision might not come until June 2015.

The current justices have taken greater interest in patent laws, and Teva's appeal could have impact beyond its industry, according to analysts.


  Support the MSF
Supporting MSF's programs to help make "a brighter tomorrow" has never been easier.
make a donation 

  Learn About MS
Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression.
learn more 


Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.

The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.

© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved